Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05887999 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT05887999 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 30 participants.
The verdict
NCT05887999, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the response of glucagon to insulin-induced low blood sugar after administration of the study drug LY3532226 in participants with type 1 diabetes mellitus (T1DM). The study will also evaluate if LY3532226 helped participants to recover from insulin-induced low blood sugar condition compared to placebo. The study will last approximately 16 weeks excluding screening period.
Interventions
- DRUG Placebo
- DRUG LY3532226
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-06-12 |
| Est. Completion | 2024-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05887999
The ClinicalTrials.gov registry entry for NCT05887999 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05887999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05887999 about?
NCT05887999 is a clinical study titled "A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus". The main purpose of this study is to evaluate the response of glucagon to insulin-induced low blood sugar after administration of the study drug LY3532226 in participants with type 1 diabetes mellitus (T1DM). The study will also evaluate if LY3532226 helped participants to recover from insulin-induc...
What is the current status of trial NCT05887999?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-06-12. Estimated completion is 2024-02-21.
What interventions are being tested in trial NCT05887999?
The interventions under investigation include: Placebo (DRUG), LY3532226 (DRUG).
Who is sponsoring clinical trial NCT05887999?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.